CryoCath CE-marks second cardiac ablation catheter:
This article was originally published in Clinica
Executive Summary
CryoCath Technologies has gained the go-ahead to sell its second cardiac ablation catheter in Europe. The Freezor Xtra device can create lesions that are significantly larger than those of the firm's original Freezor catheter, allowing surgeons to treat arrhythmias further from the AV node that require more robust lesions - such as atrial fibrillation, and ventricular tacchycardia. The Kirkland, Quebec firm plans to file for US approval for the original Freezor device in the autumn of next year. It forecasts that US approval for the Xtra catheter could come in 2004.
You may also be interested in...
California Bill To Age-Restrict Sales Of Diet Pills Further Along Than Other States’ Legislation
CA, MA and NJ legislatures remain in session with bills active proposing regulations similar to NY law effective 22 April requiring retailers, including online, to ask for proof of age when customers buying consumer health products containing ingredients labeled or promoted for weight loss and bodybuilding benefits appear younger than 18.
CRN Has Standing For Steep Hill To Climb Challenging New York's Age-Restricted Sales
Federal judge finds “misreading of the legislation” in CRN’s argument that state “restricts access based purely on what has been said about the product or its ingredients.” But standing to challenge “means that only CRN is positioned right now to go before the court on behalf of industry,” says CEO Steve Mister.
Addition to Quest Alzheimer's Suite Looks For Biomarker P-Tau217
The test is being integrated into Quest’s AD-Detect portfolio for assessing the risk of Alzheimer’s. It is the third p-tau217 test to make news this month, after new breakthrough designations for Quanterix and Roche and Eli Lilly.